Cell-cycle arrest, apoptosis, and senescence are widely accepted as the major mechanisms by which p53 inhibits tumor formation. Nevertheless, it remains unclear whether they are the rate-limiting steps in tumor suppression. Here, we have generated mice bearing lysine to arginine mutations at one (p53 K117R
INTRODUCTION
The p53 tumor suppressor regulates multiple signaling pathways triggered by diverse cellular stresses, including DNA damage, abnormal oncogenic events, loss of normal cell contacts, and hypoxia, as well as some normal cellular processes (Vousden and Prives, 2009; Feng and Levine, 2010) . Although the molecular mechanism of p53-mediated tumor suppression is not completely understood, it is widely accepted that tumor cell growth can be inhibited by p53-mediated cell-cycle arrest, apoptotic cell death, and/or cellular senescence. p53 is regulated by an exquisite network of fine-tuning mechanisms that ensure proper responses to the various stress signals encountered by cells. In broad terms, p53 activities are controlled via protein levels, coactivator/corepressor recruitment, and a diverse array of posttranslational modifications that include acetylation, ubiquitination, phosphorylation, methylation, SUMOylation, and neddylation (Kruse and Gu, 2009 ).
Numerous studies demonstrate that nonhistone protein acetylation is critically involved in regulating diverse cellular processes such as transcription, protein folding, and cellular metabolism (Kim et al., 2006; Choudhary et al., 2009; Wang et al., 2010; Zhao et al., 2010) . p53 was the first nonhistone protein shown to be regulated functionally by acetylation and deacetylation (Gu and Roeder, 1997; Luo et al., 2000 Luo et al., , 2001 Vaziri et al., 2001) , and subsequent work has established that acetylation plays a key role in controlling promoter-specific activation of p53 targets during stress responses (Berger, 2010; Kruse and Gu, 2009 ). The major acetylation sites of human p53 include two lysine residues (K120 and K164) within the DNA-binding domain and a cluster of six lysines with the C-terminal domain. We and others recently showed that p53 is acetylated at K120 by Tip60/MOF (Sykes et al., 2006; Tang et al., 2006; Li et al., 2009 ), whereas K164 is acetylated by CBP and p300, but not Tip60/MOF (Tang et al., 2008) . Both sites are mutated in human tumors and well conserved in all species known to encode p53. Interestingly, K120 acetylation is crucial for p53-mediated apoptosis but has no obvious effect on cell-cycle arrest, whereas simultaneous loss of acetylation at all major sites abolishes the ability of p53 to induce both cell-cycle arrest and apoptosis (Tang et al., 2008) , suggesting that acetylation is essential for both p53-mediated processes. However, the role of acetylation in the most critical aspect of p53 function, its ability to suppress tumor formation, has not been addressed.
To investigate whether p53 acetylation is important for tumor suppression, we generated p53 mutant mice (p53
K117R/K117R
) in which K117 (K120 in human) is replaced by arginine. In these animals, p53-mediated apoptosis is completely abrogated, but p53-dependent cell-cycle arrest and senescence remain intact. We also established mice (p53 3KR/3KR ) in which the three acetylation sites of the DNA-binding domain (K117, K161, K162) were simultaneously replaced by arginine. Significantly, loss of acetylation at these three sites completely abolished the ability of p53 to mediate cell-cycle arrest, apoptosis, and senescence in vivo.
To evaluate whether these p53-dependent processes are required for tumor suppression, we monitored tumor formation in cohorts of p53 acetylation-deficient mice. Although p53 null mice rapidly develop spontaneous thymic lymphomas (Donehower et al., 1992; Jacks et al., 1994; Lozano, 2010) , neither p53 K117R/K117R nor p53 3KR/3KR mice are prone to early-onset tumorigenesis. Because tumor suppression can be mediated by a p53 polypeptide (e.g., p53 3KR ) that lacks the ability to induce p53-dependent cell-cycle arrest, apoptosis, and senescence, these results indicate that other aspects of p53 function are sufficient to suppress tumor formation. Strikingly, the p53 3KR mutant retains the capacity to inhibit glycolysis and reduce the levels of reactive oxygen species (ROS). These findings suggest that current views regarding the mechanism of p53-mediated tumor suppression should be reconsidered.
RESULTS

Generation of p53 K117R Knockin Mice
To elucidate the physiological functions of p53 acetylation, we first used mass spectrometric (MS/MS) analysis of mouse p53 protein to confirm that lysine 117 (K117) (corresponding human lysine 120) is indeed acetylated (see Figure S1 available online). Mouse embryonic stem (ES) cells were then electroporated with a knockin-targeting construct designed to replace lysine codon 117 with an arginine codon (K117R) ( Figure S2A ). Properly targeted G418-resistant clones were identified by Southern analysis ( Figure S2B ), and two independent clones were injected into C57BL/6 blastocysts to achieve germline transmission of the p53 K117R allele. The heterozygous F1 mice were then bred with Rosa26-Cre transgenic mice to delete the LoxP-flanked neomycin resistance gene (neo) from the targeted allele. The resultant neo-deleted heterozygous p53 K117R/+ mice were intercrossed, and their progeny was genotyped by PCR ( Figure S2C ). Of note, homozygous p53 K117R/K117R mice were obtained at the expected Mendelian ratio ( Figure S2D ) and displayed no apparent developmental abnormalities. Expression of the mutant gene product was confirmed by sequence analysis of p53 cDNAs from p53 K117R/K117R cells ( Figure S2E ).
K117R Mutation Has No Effect on p53 Stabilization but Completely Abolishes p53-Mediated Apoptosis
Previous studies in human cell lines indicate that K120 acetylation is crucial for apoptosis but has no obvious effect on p53 protein stability or p53-mediated cell-cycle arrest (Sykes et al., 2006; Tang et al., 2006) . To ascertain whether K117 acetylation regulates p53 apoptotic function similarly in mice, we analyzed p53-dependent apoptosis in p53 K117R/K117R thymocytes subjected to ionizing radiation (IR). The levels of p53 protein were induced in a similar fashion by IR in p53 K117R/K117R and wild-type (WT) thymocytes ( Figure 1A ), and IR-induced p53 phosphorylation (p-p53) remained intact. Although IR-induced transactivation of p21, a p53 target gene required for cell-cycle arrest, was observed in p53 K117R/K117R thymocytes, IR induction of PUMA, an apoptotic p53 target, was completely abrogated. Moreover, immunostaining for the active form of caspase 3 revealed that IR-induced apoptosis was also abolished in p53 K117R/K117R thymocytes ( Figure 1B ). To corroborate these findings, thymocytes were isolated from both p53 K117R/K117R and WT mice 4 hr after irradiation and stained with annexin V-FITC. FACS analysis showed that IR-induced apoptosis was virtually abrogated in p53 K117R/K117R thymocytes ( Figures 1C   and 1D ). To examine whether these effects are cell-type specific, we also examined apoptotic responses in other tissues sensitive to DNA damage. As shown in Figure 1E , K117R mutation completely blocked the apoptotic response in testis, intestine, and spleen. Detailed analysis again showed that p53-mediated activation of proapoptotic target genes and p53-dependent apoptosis were ablated in p53 K117R/K117R spleens ( Figure S3 ).
These data indicate that K117 acetylation is required for p53-dependent apoptosis in vivo.
p53-Dependent Cell-Cycle Arrest and Senescence Remain Intact in p53 K117R/K117R MEFs To determine whether the K117R mutation affects p53-dependent cell-cycle arrest and senescence, we compared the response of p53 K117R/K117R and WT mouse embryonic fibroblasts (MEFs) to treatment with the genotoxic agent doxorubicin (Dox). As shown in Figure 2A , stabilization and phosphorylation of p53 K117R polypeptides occurred normally in response to Dox. Consistent with results obtained in mouse tissues (Figure 1A) , p53-mediated transactivation of PUMA, but not p21 or Mdm2, was completely abrogated in p53 K117R/K117R MEFs ( Figure 2A ). Moreover, p53 K117R/K117R MEFs were also defective for induction of other known proapoptotic p53 target genes such as NOXA and DR5 ( Figure 2B ). To examine whether the K117R mutation affects p53-mediated growth arrest, p53 K117R/K117R and WT MEFs were pulse labeled for BrdU, fixed in 70% ethanol, and double stained with anti-BrdU antibody and DAPI. As shown in Figure 2C , IR treatment reduced the levels of BrdU incorporation to a comparable degree in both p53 K117R/K117R and WT MEFs ( Figures 2C and 2D ). In addition we compared the growth and senescence of WT and p53 K117R/K117R MEFs following a standard 3T3 proliferation protocol. As expected, the expression levels of p53, p21, and Arf increased gradually upon passage of both WT and p53 K117R MEFs ( Figure 2E ). Although p53 K117R/K117R cells proliferated slightly faster than WT MEFs ( Figure S4 ), both reached senescence similarly at passage 7 ( Figure 2F ). Together, these data suggest that the p53 K117R mutant retains its ability to induce both cell-cycle arrest and senescence in vivo.
Loss of Acetylation at Three Sites of Mouse p53
Abrogates Transcriptional Induction of Both p21 and PUMA Although K117 acetylation is required for the p53-mediated apoptotic response in vivo (Figure 1 ), we observed no obvious differences between p53 K117R/K117R and p53 WT cells with respect to either cell-cycle arrest or senescence. Notably, our recent study showed that elimination of multiple acetylation sites on human p53 abrogates both the growth arrest and apoptosis functions of p53 (Tang et al., 2008) . To explore this possibility, we sought to generate a mutant mouse that would also be defective for p53-dependent cell-cycle arrest and senescence. Our previous studies indicated that K164 acetylation of human p53 Figure S4 .
(corresponding to K161 of mouse p53) is critical for p53-mediated cell-cycle arrest (Tang et al., 2008) . Interestingly, as shown in Figure 3A , both K161 and K162 of mouse p53 (corresponding to K164 and Q165 of human p53) are evolutionarily conserved in all species, with the exception of Q165 in human. Moreover, mass spectrometry analysis of mouse p53 revealed that both K161 and K162 are acetylated in vivo ( Figure 3B ). Therefore, we generated an expression plasmid encoding a mouse p53 mutant (p53 3KR ) in which all three acetylation sites (K117, K161, and K162) are replaced by arginine. As expected, expression of WT mouse p53 in p53 null human H1299 cells induced transcription of both p21 and PUMA (lane 2, Figure 3C ). Moreover, consistent with the data from p53 K117R/K117R mice ( Figure 2A ), expression of p53 K117R induced p21, but not PUMA, transcription (lane 4). Strikingly, loss of acetylation at all three sites (K117R, K161R, and K162R: p53 3KR ) completely abolished the induction of both p21 and PUMA ( Figure 2A , lane 3). Because the three mutated residues all reside within the DNA-binding domain, we examined the sequence-specific DNA-binding properties of p53 3KR in a chromatin immunoprecipitation (ChIP) assay. As shown in Figure 3D , the DNA-binding activities of the WT and p53 3KR mutant forms of mouse p53 were indistinguishable at a number of p53 target promoters, including p21, PUMA, and Mdm2. Moreover, p53 3KR readily induced expression of endogenous Mdm2
(lane 3, Figure 3C ). Thus, we have identified a mouse p53 mutant (p53 3KR ) that retains its ability to bind DNA and activate RNA transcription but is likely defective for both p53-dependent cell-cycle arrest and apoptosis. To elucidate the role of p53 acetylation in vivo, we used a similar knockin-targeting strategy to introduce a p53 3KR allele into the germline of mice (Figures S5A and S5B) . Upon intercrossing p53 3KR/+ heterozygotes, viable p53 3KR/3KR homozygous mice were obtained at normal Mendelian ratios (Figures S5C and S5D) , and expression of the mutated p53 3KR allele was confirmed by sequence analysis of cDNA from p53 3KR/3KR cells ( Figure S5E ). To examine p53
3KR
-mediated function in vivo, we analyzed p53-dependent apoptosis in p53 3KR/3KR thymocytes subjected to IR. As expected, apoptosis was completely abrogated in p53 3KR/3KR thymocytes (Figures 4A and 4B) . To test whether the p53 3KR mutation affects cell-cycle arrest, MEFs from embryonic day 13.5 were treated with Dox. As shown in Figure 4C , Dox induced the stabilization and phosphorylation of p53 polypeptides to a comparable degree in p53 3KR/3KR and WT MEFs. In accordance with results obtained using exogenous p53 expression ( Figures 3C and 3D ), Dox induced Mdm2 expression in both p53 3KR/3KR and WT cells (albeit to a slightly lesser degree in p53 3KR/3KR MEFs), whereas p21 and PUMA induction was specifically ablated in p53 3KR/KR MEFs ( Figure 4C ). Similar results were also obtained when p53-mediated responses were examined under different types of stress conditions such as etoposide, UV, and oxidative stress ( Figures S6A-S6C ). Moreover, by using BrdU incorporation analysis, we found that p53 3KR/3KR cells were defective for IR-induced arrest of cell proliferation (Figures 4D and S6D) . Consistent with these observations, p53 protein levels were induced to a similar degree in thymocytes from both WT and p53 3KR/3KR mice ( Figure 4E ), whereas IR induction of p21 and PUMA transcription was completely abrogated ( Figure 4E ). Moreover, to exclude the possibility that the mutant cells die with slower kinetics, we compared the levels of apoptosis induced by DNA damage in p53-WT, p53 K117R/K117R , p53
, and p53 null mice. To this end, p53-WT, p53 K117R/K117R , p53
, and p53 null mice were treated with 12.5 Gy of g-radiation, and thymocytes isolated from these mice at different time points after irradiation (4, 8, and 24 hr) were analyzed for levels of apoptosis. As shown in Figure 4F , the active form of caspase 3 was readily detected in p53-WT mice at 4 and 8 hr after irradiation, indicating strong IR-induced apoptosis under these conditions. In contrast, significant apoptosis was not observed in thymocytes isolated from p53 K117R/K117R , p53
, or p53 null mice at any time point after g-radiation.
Finally, to confirm whether p53 3KR is also defective for induction of other p53 target genes involved in cell-cycle arrest and apoptosis, mRNA levels in WT and mutant MEFs were compared by quantitative real-time RT-PCR. Significantly, none of the key p53 targets involved in cell-cycle arrest (i.e., p21, 14-3-s, cyclin G1/ccng1, and GADD45) or apoptosis (Bax, PUMA, NOXA, and DR5) was induced by Dox in p53 3KR cells ( Figures 5A and 5B).
Indeed, the expression levels of these target genes were virtually indistinguishable in p53 3KR mutant cells and p53 null cells. Taken together, these data indicate that the p53 3KR mutation abrogates both p53-mediated cell-cycle arrest and apoptosis without affecting either genotoxin-induced p53 stabilization or transactivation of certain target genes such as Mdm2.
The p53 3KR/3KR Mutant Fails to Induce p53-Dependent Senescence In addition to cell-cycle arrest and apoptosis, numerous studies have identified senescence as an alternative mechanism of p53-mediated tumor suppression. In this regard we found that Dox-induced transactivation of several p53 target genes, including PAI-1 and PML, was also defective in p53 3KR/3KR cells ( Figures S7A and S7B) . Therefore, we examined whether p53 3KR/3KR MEFs are competent to undergo p53-dependent cellular senescence. As shown in Figure 5C , p53 3KR/3KR MEFs proliferated slightly slower than p53 À/À MEFs but dramatically faster than WT MEFs. As expected, WT MEFs reached senescence around passage 7; in contrast both p53 À/À and p53 3KR/3KR MEFs continued to proliferate and showed no evidence of senescence ( Figure 5D ). Notably, p53 and Arf transcription was gradually induced on passage of p53
MEFs, similar to p53 null cells, but induction of p21 expression was not observed in p53 3KR/3KR MEFs ( Figures 5E and 5F ). In addition we examined oncogene-induced senescence in these cells. As expected, very high levels of senescence were observed in p53-WT-MEF cells upon oncogene (H-ras) expression ( Figures S7C and S7D) ; in contrast we were unable to detect senescence of either p53-3KR or p53 null cells under these conditions. Taken together, these data demonstrate that p53 3KR/3KR cells fail to undergo p53-dependent senescence. , and p53 À/À mice upon DNA damage treatment. Mice were either untreated or exposed to 12.5 Gy of g irradiation; thymocytes were isolated at different time points after irradiation and analyzed for the level of cleaved caspase 3. b-actin was used as a loading control. See also Figures S5 and S6 . RelaƟve mRNA levels ) mice. In accord with published data by Donehower et al. (1992) , Jacks et al. (1994) , and Lozano (2010), p53 null mice rapidly developed spontaneous tumors, primarily thymic lymphomas, and most died by 6 months of age. Although K117 acetylation is required for the p53-mediated apoptotic response in vivo, we observed no differences between p53 K117R/K117R and WT mice with respect to either normal development or spontaneous tumor formation ( Figure 6A ). These results suggest that other functions of p53 (e.g., cell-cycle arrest and/or senescence) are sufficient to prevent early-onset spontaneous tumor formation. However, most p53 3KR/3KR animals remained healthy up to at least 16 months of age. Thus, despite their inability to mediate p53-dependent cell-cycle arrest, apoptosis, or senescence, none of the p53 3KR/3KR mice succumbed to early-onset spontaneous tumors ( Figure 6A ). Indeed, only 3 of the 27 p53 3KR/3KR mice developed tumors ( Figure 6A ), and sequence analysis uncovered de novo mutations of the p53 3KR gene in the tumor tissues of these 3 p53 3KR/3KR mice ( Figure S7E ), further validating that p53-3KR retains its function as a tumor suppressor. These data indicate that the combined loss of p53-mediated cell-cycle arrest, senescence, and apoptosis is not sufficient to abrogate the tumor suppression activity of p53.
p53 3KR Retains Its Ability to Regulate the Expression of Metabolic p53 Target Genes
Cell-cycle arrest, senescence, and apoptosis are widely viewed as the major mechanisms of p53-mediated tumor suppression; yet, our data suggest that these classical p53 responses are not essential for tumor suppression. Thus, other p53 functions, particularly those retained by p53
3KR
, may be more relevant to suppression of early-onset tumorigenesis. To explore this possibility, we examined p53 3KR -mediated transcriptional activation in a panel of p53 target genes implicated in unconventional functions of p53. Notably, quantitative real-time RT-PCR revealed that the transcription of two known p53 target genes involved in metabolic regulation, GLS2 and TIGAR (Hu et al., 2010; Suzuki et al., 2010; Bensaad et al., 2006) , was fully induced by Dox in p53 3KR/3KR cells ( Figure 6B ). GLS2 encodes a mitochondrial glutaminase that modulates mitochondrial respiration and ATP generation by catalyzing the hydrolysis of glutamine to glutamate, whereas TIGAR encodes a fructose bisphosphatase that downregulates glycolysis by reducing cellular levels of fructose-2, 6,-bisphosphate. Further analysis showed that the steady-state levels of GLS2 and TIGAR proteins were induced by stress in both WT and p53 3KR/3KR MEFs, but not in p53
À/À cells ( Figure 6C ). To validate the p53 acetylation status in these cells, p53 +/+ and p53 3KR/3KR MEFs were first treated with 0.2 mg/ml Dox for 8 hr and were then processed for immunoprecipitation analysis. Cell lysates were immunoprecipitated with anti-AcK120-p53, anti-AcK164-p53, or anti-AcK CT-p53 antibodies and blotted with anti-p53 (CM5) antibody. As expected, acetylation of p53 at each of these sites was readily induced by DNA damage in WT MEFs (lane 4, Figure 6D ). In p53
MEFs, however, damage-induced acetylation of the C-terminal lysines was retained, but no detectable acetylation was observed at either K117 or K161 ( Figure 6D , lane 6). Likewise, K117 acetylation was specifically abrogated in p53
MEFs, whereas acetylation of the other sites remained normal ( Figure 6D , lane 5). Moreover, ChIP assays revealed that both WT p53 and p53-3KR proteins bind equally well to the promoters of the GLS2 and TIGAR metabolic target genes. Thus, although p53 3KR fails to transactivate most p53 target genes, including those involved in p53-mediated cell-cycle arrest, apoptosis, and senescence, it retains the ability to induce the metabolic target genes GLS2 and TIGAR in response to stress. Finally, increased glucose uptake is a common characteristic of tumor cells that preferentially metabolize glucose by aerobic glycolysis instead of oxidative phosphorylation, and several studies have shown that p53 expression leads to transcriptional downregulation of the GLUT3 (Kawauchi et al., 2008; SchwartzenbergBar-Yoseph et al., 2004) . As expected, GLUT3 expression is dramatically increased in p53 À/À cells relative to WT MEFs (Figure 6F) . Significantly, the levels of GLUT3 transcript remain low in p53 3KR/3KR cells, suggesting that p53 3KR can inhibit GLUT3 expression in a manner similar to WT p53 ( Figure 6F ). Together, these data demonstrate that p53 3KR retains the capacity to regulate the expression of multiple metabolic p53 target genes.
The Inhibitory Effects of p53 3KR in Regulating Glucose
Uptake, Glycolysis, ROS, and Colony Formation Cancer cells consume large quantities of glucose for glycolysis. It has been reported that inactivation of p53 leads to high glucose uptake (Zhang et al., 2011 , and p53 À/À MEFs. As shown in Figure 7A , relative glucose uptake was approximately 3-fold higher in p53 À/À MEFs than p53 +/+ MEFs, validating that p53 loss significantly promotes glucose uptake (Zhang et al., 2011 Ashcroft et al. (1972) . As shown in Figure 7B , the glycolysis rate of p53 À/À MEF cells was about 60% higher than that of WT MEFs, indicating that p53 loss indeed increases the rate of glycolysis in vivo. In contrast the glycolysis rate of p53 regulate the levels of ROS in cancer cells (Bensaad et al., 2006; Hu et al., 2010; Suzuki et al., 2010) . Thus, we compared the levels of ROS in p53 +/+ , p53 3KR/3KR
, and p53 À/À MEFs. As shown in Figure 7C , the ROS levels of p53 À/À MEFs were about 85%
higher than those of WT cells, suggesting that p53 loss signifi- cantly increases ROS levels in vivo. Conversely, the ROS levels of p53
MEF cells were indistinguishable from those of WT cells. Finally, we tested whether expression of p53-3KR is able to suppress colony formation of cancer cells in a manner analogous to GSL2 expression, as reported by Hu et al. (2010) and Suzuki et al. (2010) . To this end, p53 null H1299 cells were transfected for 48 hr with an empty expression vector, Flag-GLS2 expression vector alone, or Flag-p53-3KR expression vector and Flag-Mdm2 expression vector ( Figure 7D ). As shown in Figures 7E and 7F , p53-3KR expression significantly reduced colony formation. Notably, in contrast to GLS2 expression, Mdm2 expression in these p53 null cells had no obvious effect, suggesting that Mdm2 induction by p53-3KR may not contribute to its tumor suppression activity ( Figure 7E ). Together, these data suggest that p53-3KR retains its tumor suppressor activity, at least in part, through its ability to regulate energy metabolism and ROS levels in vivo.
DISCUSSION
Because p53 mutations are the most common genetic lesions associated with human cancer, a major objective of molecular oncology is to elucidate the mechanisms by which p53 suppresses tumor formation. Our studies of mice expressing acetylation-defective p53 mutants revealed that acetylation differentially regulates p53 function in cell-cycle arrest, apoptosis, and senescence. This circumstance afforded us the opportunity to test whether these p53 functions are required for p53-mediated tumor suppression. Surprisingly, we found that the combined loss of p53-dependent cell-cycle arrest, apoptosis, and senescence is not sufficient to abrogate the tumor suppression activity of p53. By demonstrating that the canonical functions of p53 in cell-cycle arrest, apoptosis, and senescence are not absolutely required for tumor suppression, these results challenge the prevailing view of how p53 lesions promote human cancer.
Reassessing the Mechanisms of p53-Mediated Tumor Suppression
Through its ability to induce cell-cycle arrest, apoptosis, or senescence in response to various types of stress, p53 is thought to suppress tumor formation by preventing inappropriate expansion of cells with malignant potential. Although nontranscriptional functions of p53 may also contribute to tumor suppression, recent studies of mice bearing defined mutations of the p53 transactivation domains indicate that its role as a transcription factor is essential for p53-mediated tumor suppression (Brady et al., 2011) .
The ability of p53 to induce cell-cycle arrest is mediated in large part by transcriptional activation of p21
Cip1
, which encodes an inhibitor of cyclin-dependent kinases (el-Deiry et al., 1993) . The induction of p21 expression is sensitive to even low levels of p53 protein, suggesting that a temporary G1 or G2 block, as induced by mild damage or stress, allows cells to survive until damage has been resolved or stress removed. In addition, p21 is also critical for p53-dependent senescence-an irreversible cell-cycle arrest that can be elicited by DNA damage, oncogene activation, or telomere dysfunction. However, unlike p53 null mice, p21 null animals are not prone to early-onset tumorigenesis, although p21 deficiency extends longevity and rescues stem cell function in mice with dysfunctional telomeres (Deng et al., 1995; Choudhury et al., 2007) . This observation implies that the apoptotic functions of p53 may be more relevant to tumor suppression, or may contribute to tumor suppression in a compensatory fashion when p53-mediated cell-cycle arrest and/or senescence is compromised. Nevertheless, early-onset tumor formation is not observed in mice expressing an apoptosis-defective mutant (p53 R172P ) that retains the cell-cycle arrest and cellular senescence functions of p53 (Liu et al., 2004; Cosme-Blanco et al., 2007; Van Nguyen et al., 2007) . Likewise, mice lacking PUMA, a p53-target gene required for p53-dependent apoptosis in a broad range of cell types , are still resistant to early-onset tumorigenesis (Michalak et al., 2008) . Interestingly, a p53 mutant (p53 25, 26 ) deficient for p53-mediated cell-cycle arrest and apoptosis, but not senescence, was recently shown to retain the ability to inhibit Kras G12D -induced lung carcinogenesis (Brady et al., 2011) . Thus, despite the fact that the canonical functions of p53 in cell-cycle arrest, apoptosis, and senescence are widely accepted as the major mechanisms of p53-mediated tumor suppression, it has never been formally tested whether they are the rate-limiting steps in vivo.
Numerous studies suggest that cell-cycle arrest, apoptosis, and senescence are crucial for p53-mediated tumor suppression. Nonetheless, it is unclear why these aspects of p53 function are required for tumor suppression only under certain biological settings. For example PUMA is a critical target for p53-mediated apoptosis, but PUMA knockout mice fail to develop early-onset spontaneous tumors. Yet, loss of PUMA apparently accelerates Em-Myc-mediated lymphomagenesis (Garrison et al., 2008; Michalak et al., 2009 ). Likewise, p53-mediated senescence is apparently critically involved in suppressing Kras G12D -induced lung carcinogenesis (Brady et al., 2011) . It is possible that p53 can suppress tumor formation with distinct mechanisms under different physiological settings. Moreover, because p53 lesions are observed in a broad spectrum of human cancers, it will be interesting to ascertain whether these aspects of p53 function are differentially required for tumor suppression in different types of cancers. Clearly, our studies demonstrate that p53-mediated cell-cycle arrest, apoptosis, and senescence are not essential for suppressing early-onset spontaneous tumorigenesis, which raises a fundamental question regarding whether these well-studied activities of p53 are truly the most important functions of tumor suppression in general.
A Role for p53-Mediated Metabolic Regulation in Tumor Suppression? Although p53-mediated cell-cycle arrest, apoptosis, and senescence are presumed to be the primary mechanisms by which p53 inhibits oncogenesis, the phenotype of p53 3KR/3KR mice indicates that other, as yet undetermined, functions of p53 are also important for tumor suppression. In principle the relevant aspects of p53 function should be retained by the p53 3KR mutant polypeptide. As such, it is intriguing that p53 3KR , which fails to transactivate a number of genes involved in p53-mediated cellcycle arrest, apoptosis, and senescence, still maintains the capacity to regulate p53 target genes implicated in metabolic control, including GLS2, TIGAR, and GLUT3. In resting cells under normal aerobic conditions, the pyruvate generated by glycolysis can be fed into the mitochondrial tricarboxylic acid (TCA) cycle for efficient ATP generation via oxidative phosphorylation. However, proliferating cells undergo a metabolic reprogramming to ''aerobic glycolysis'' in which glycolytic flux is increased, oxidative phosphorylation is suppressed, pyruvate is converted primarily to lactate, and intermediates of the TCA cycle are diverted into anabolic pathways to facilitate cell growth (Vander Heiden et al., 2009) . A similar metabolic switch to aerobic glycolysis, termed the Warburg effect, is also observed in tumor cells, and recent studies suggest that p53 normally inhibits this process by limiting glycolytic flux through multiple mechanisms (Gottlieb and Vousden, 2010; Feng and Levine, 2010; Warburg, 1956) . For example p53 suppresses the expression of glucose transporters such as GLUT3 (Kawauchi et al., 2008; Schwartzenberg-Bar-Yoseph et al., 2004) , although the precise mechanism of this repression needs further elucidation. p53 also modulates production of glutamine, an alternative to glucose as a fuel for bioenergetic pathways, by transactivating the gene for GLS2, a mitochondrial glutaminase that converts glutamine to glutamate (Hu et al., 2010; Suzuki et al., 2010) . As such, GLS2 promotes energy metabolism by providing a source of a-ketoglutarate for the TCA cycle and antioxidant defense by providing glutamate for glutathione synthesis. Notably, GLS2 is downregulated in human cancer, and GLS2 overexpression reduces the in vitro proliferation and colony-forming potential of tumor cells (Hu et al., 2010; Suzuki et al., 2010) . The gene encoding TIGAR was also identified as a key p53 target implicated in energy metabolism and ATP generation (Bensaad et al., 2006) . By lowering levels of fructose-2, 6,-bisphosphate, TIGAR normally functions to reduce glycolytic flux and direct glucose to the pentose phosphate pathway. Thus, p53 inactivation promotes metabolic changes similar to the Warburg effect by increasing both glycolytic flux and lactate production (Gottlieb and Vousden, 2010; Feng and Levine, 2010) . Although cell-cycle arrest, senescence, and apoptosis are abrogated in p53 3KR/3KR cells, p53 3KR retains its ability to suppress glucose uptake and glycolysis. Moreover, consistent with the fact that both GLS2 and TIGAR are critically involved in regulating ROS in vivo, p53 3KR retains its capacity to reduce ROS levels, and expression of p53 3KR leads to suppression of colony-formation ability of cancer cells. In light of these results, p53 3KR may block tumor formation, at least in part, by inhibiting the metabolic shift to aerobic glycolysis and reducing ROS levels in vivo. As such, the ability of p53 to regulate the metabolic state and antioxidant defense may serve as independent mechanisms of tumor suppression that are sufficient to suppress early-onset spontaneous tumorigenesis when the p53-mediated pathways of cell-cycle arrest, apoptosis, and senescence are simultaneously inoperative. Clearly, the molecular mechanisms by which p53 regulates its metabolic target genes need further elucidation. Based on our studies, the requirements for activating p53-mediated metabolic regulation are apparently different from those that modulate cell-cycle arrest, apoptosis, and senescence. It will be interesting to know whether other recognized acetylation sites, such as C terminus lysine residues and K320, or other types of p53 modification, such as phosphorylation or methylation, modulate the expression of these metabolic targets of p53 in vivo. 
Protein Purification and Mass Spectrometry
To purify the acetylated mouse p53 protein, H1299 cells were cotransfected with pCin4-p53-Flag and CMV-Tip60 and cultured for 20 hr, then the transfected H1299 cells were treated with 1 mM TSA and 5 mM nicotinamide for 6 hr before harvest. Cells were collected and lysed in the Flag-lysis buffer (50 mM Tris-HCl [pH 7.9], 137 mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.2% sarkosyl, 10% glycerol, and fresh proteinase inhibitor cocktail [Sigma-Aldrich]) plus 2 mM TSA and 10 mM nicotinamide, and the cell extracts were immunoprecipitated with the anti-Flag monoclonal antibody-conjugated M2 agarose beads (Sigma-Aldrich). The Flag peptide-eluted material was resolved by 8% SDS-PAGE. The p53 bands were excised from the gel and subjected to tryptic digestion and mass spectrometry.
Colony Formation Assay H1299 cells were transfected with either empty vector or FLAG-taggedp53, -GLS2, and -Mdm2 expression plasmids for 48 hr. Cells were then split and seeded into 10 cm dishes at the density of 1,000 cells per dish and cultured under the selection of G418 (600 mg/ml) for 12 days. Cells were stained with crystal violet solution, and visible colonies were counted. Ashcroft et al. (1972) . To measure glycolysis rate, 2.5 3 10 5 MEFs were seeded in each well of 6-well plates and cultured overnight. MEF cells were washed once with PBS and once with Krebs buffer, and 1 ml of Krebs buffer was added to cells. After the cells were incubated for 30 min at 37 C, 0.5 ml of Krebs buffer containing 10 mM glucose and 10 mCi of 5-[ 3 H]glucose was added. Following incubation for 1 hr at 37 C, 500 ml of 0.2 N HCl was added to the cells to stop the reaction, then scrape the cells, and 500 ml cell suspension aliquots in triplicate were transferred to uncapped 1.5 ml Eppendorf tubes that then were put into a scintillation vial containing 1.0 ml of H 2 O in such a way that the water in the vial and the contents of the 1.5 ml Eppendorf tube were not allowed to mix. The vials were sealed, and diffusion was allowed to occur for a minimum of 24 hr at room temperature. The amounts of diffused 3 H 2 O in the vial, representing the glycolysis rate, were determined by scintillation counting.
Measurement of Glucose Uptake and Glycolysis Rate
Measurement of ROS
A total of 5 3 10 5 p53 +/+ and p53 3KR/3KR and p53 À/À MEFs were seeded in 6 cm dishes, following incubation at 37 C overnight, the cells were collected and lysed for ROS assay using Mouse Reactive Oxygen Species ELISA kit (E03R0070) from Life Science Advanced Technologies. Briefly, 100 ml of samples or standards with known concentration of ROS was added to the triplicate microtiter plate wells precoated with anti-ROS antibody, and then 50 ml ROS-HRP conjugate was added to each well, mix and incubate microtiter plate at 37 C for 1 hr, then the wells were washed with 400 ml 13 washing solution for five times and incubated for 15 min with addition of 50 ml substrates for HRP enzyme. The enzyme-substrate reaction was terminated by adding 50 ml of stop solution to each well, and the optical density (OD) at a wavelength of 450 nm was measured immediately using mQuant Scanning Microplate Spectrophotometer (BioTek Instruments). The concentration of ROS in each sample was then determined by comparing the OD of each sample to the standard curve.
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